When evaluating cjc-1295 dac prijs (pricing dynamics) for laboratory acquisition, researchers must weigh raw milligram cost against verified purity metrics. High-grade CJC-1295 DAC requires rigorous RP-HPLC purification, mass spectrometry validation, and strict endotoxin limits. Investing in fully characterized, USA-manufactured reagents ensures reproducible receptor-binding assays and reliable downstream IGF-1 data without batch-to-batch contamination risks.
When evaluating cjc-1295 dac prijs (pricing dynamics) for laboratory acquisition, researchers must weigh raw milligram cost against verified purity metrics. High-grade CJC-1295 DAC requires rigorous RP-HPLC purification, mass spectrometry validation, and strict endotoxin limits. Investing in fully characterized, USA-manufactured reagents ensures reproducible receptor-binding assays and reliable downstream IGF-1 data without batch-to-batch contamination risks.
In biomedical research, searching for the optimal cjc-1295 dac prijs requires a clear understanding of the parameters that dictate synthetic peptide value. While catalog prices vary widely across domestic and international suppliers, the raw purchase price of CJC-1295 with Drug Affinity Complex (DAC) is only one component of experimental economy. Substandard reagents that contain residual trifluoroacetic acid (TFA), truncated peptide fragments, or bacterial endotoxins can invalidate weeks of cellular culture assays or rodent model trials, resulting in substantial net loss of laboratory resources.
To establish true procurement value, principal investigators must evaluate peptides based on purity verification rather than milligram cost alone. High-purity reagents supplied with lot-specific documentation ensure that observed biological phenomena derive solely from target peptide activity. PX1 Research prioritizes rigorous quality control by manufacturing compounds in GMP-compliant facilities and validating every batch through independent ISO 17025 accredited laboratories.
CJC-1295 DAC is a modified 29-amino-acid synthetic peptide analog of endogenous growth hormone-releasing hormone (GHRH). The native GHRH molecule is rapidly degraded in vivo by enzymatic cleavage, primarily by dipeptidyl peptidase IV (DPP-IV), resulting in an extremely short plasma half-life of several minutes. To overcome this limitation in experimental models, molecular biophysicists introduced D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27, yielding a tetrasubstituted GHRH(1-29) core.
The defining modification of CJC-1295 DAC is the addition of a lysine residue at the C-terminus bound to a maleimide-containing linker, known as the Drug Affinity Complex (DAC). In animal models and physiological buffer environments, this maleimide group selectively forms a covalent bond with the free thiol group on cysteine-34 of circulating serum albumin. This irreversible conjugation protects the peptide backbone from enzymatic degradation and renal clearance, extending its functional half-life to several days in vivo.
As a synthetic GHRH research peptide, CJC-1295 DAC binds specifically to the growth hormone-releasing hormone receptor (GHRHR), a class B G-protein coupled receptor located on somatotropic cells in the anterior pituitary. Upon ligand binding, the receptor undergoes a conformational change that activates adenylate cyclase, leading to elevated intracellular cyclic adenosine monophosphate (cAMP) levels and protein kinase A (PKA) pathway activation.
Preclinical studies suggest that unlike native GHRH, which induces transient pulses of pituitary stimulation, CJC-1295 DAC provides extended, basal stimulation of somatotropes. This sustained activation leads to persistent transcription and secretion of endogenous growth hormone (GH). Elevated GH concentrations subsequently stimulate hepatic expression of insulin-like growth factor 1 (IGF-1), establishing a prolonged endocrine profile useful for studying downstream metabolic and tissue regeneration cascades.
When purchasing high-purity analytical compounds, verifying chemical identity and purity is essential for data integrity. Reverse-phase high-performance liquid chromatography (RP-HPLC) is used to quantify peptide purity, ensuring that target sequences comprise at least 98% of total peak area. Concurrently, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or electrospray ionization (ESI) mass spectrometry confirms the exact molecular weight (3647.28 Da for CJC-1295 DAC), confirming correct sequence synthesis and complete DAC attachment.
Bacterial endotoxin contamination poses a significant risk to cell culture viability and animal model physiological stability. Gram-negative bacterial lipopolysaccharides (LPS) can trigger inflammatory cascades, confounding experimental measurements of cytokine release, cellular proliferation, or tissue repair. PX1 Research enforces strict endotoxin screening (<0.01 EU/mg) on all lots, providing full transparency through accessible Certificates of Analysis (COAs) for every CJC-1295 DAC lot.
Understanding the operational differences between growth hormone secretagogues helps researchers select the appropriate compound for specific experimental designs. The primary distinction between CJC-1295 DAC and CJC-1295 without DAC lies in pharmacokinetic half-life; the non-DAC variant (often referred to as Modified GRF 1-29) lacks the albumin-binding maleimide affinity complex, resulting in rapid clearance suitable for mimicking physiological GH pulses.
When evaluating broader GHRH analogs, researchers frequently compare CJC-1295 DAC to Sermorelin and Tesamorelin. Sermorelin represents the truncated 1-29 sequence of native GHRH with a brief half-life, whereas Tesamorelin features a trans-3-hexenoic acid modification tailored for specific lipid metabolism models. Additionally, researchers studying synergistic GH release often combine GHRH analogs with growth hormone secretagogue receptor (GHSR) agonists such as Ipamorelin or GHRP-2 to examine dual-pathway activation of somatotropes.
Proper reconstitution and handling protocols are vital to preserve peptide integrity and prevent premature hydrolysis or aggregation. Lyophilized CJC-1295 DAC should be stored in a controlled freezer environment at -20°C to -80°C upon receipt, shielded from light exposure. Before opening, vials should be allowed to equilibrate to room temperature to prevent condensation from forming inside the container.
Reconstitution should be performed using sterile bacteriostatic water (containing 0.9% benzyl alcohol) or laboratory-grade sterile water for immediate use assays. The solvent should be introduced gently along the glass wall of the vial rather than sprayed directly onto the lyophilized cake. Gentle swirling is recommended; mechanical agitation or violent shaking must be avoided, as shear forces can disrupt peptide tertiary structures. Once reconstituted, solutions should be aliquoted and stored at 2°C to 8°C for short-term assays, or refrozen to prevent cyclic freeze-thaw degradation.
In vitro data indicate that sustained elevation of IGF-1 driven by CJC-1295 DAC administration accelerates extracellular matrix remodeling and cellular proliferation in fibroblast and myoblast culture lines. Researchers investigating musculoskeletal wound healing utilize CJC-1295 DAC to examine collagen synthesis rates, satellite cell activation, and tendon-to-bone interface repair in rodent injury models.
Furthermore, animal study models exploring metabolic homeostasis utilize long-acting GHRH analogs to evaluate changes in body composition, nitrogen retention, and lipolysis kinetics over multi-week experimental windows. By maintaining steady-state GH and IGF-1 signaling without requiring multiple daily micro-administrations, CJC-1295 DAC reduces stress variables in laboratory animals, supporting clearer dataset acquisition in long-term physiology research.
For academic institutions, biotechnology enterprises, and contract research organizations (CROs), securing consistent bulk supplies directly impacts budget allocation and longitudinal trial reproducibility. Establishing wholesale lab accounts provides institutional pricing advantages, batch reservation options, and predictable supply schedules that mitigate laboratory downtime.
PX1 Research maintains a robust domestic supply chain, manufacturing peptides in USA facilities and maintaining inventory hubs in California and Arizona. Orders placed Monday through Friday receive same-day dispatch, eliminating international customs delays, unpredictable transit degradation, and documentation gaps. Reviewing detailed educational materials in the PX1 Research library allows procurement officers to make informed sourcing decisions backed by comprehensive analytical data.
Hoe wordt de cjc-1295 dac prijs bepaald in laboratoriumonderzoek?
De cjc-1295 dac prijs wordt hoofdzakelijk bepaald door de synthesecomplexiteit, de efficiëntie van de RP-HPLC zuivering, en het niveau van analytische testen (zoals MS en endotoxine-analyses). Hoge zuiverheid (>98%) en betrouwbare batch-documentatie vereisen strengere kwaliteitsbewaking, wat een hogere analytische waarde vertegenwoordigt voor onderzoekslaboratoria.
What is the primary difference between CJC-1295 DAC and CJC-1295 No DAC?
The key difference is the inclusion of the Drug Affinity Complex (DAC), a maleimide linker that covalently binds to serum albumin in vivo. This extends the half-life of CJC-1295 DAC to several days, whereas CJC-1295 No DAC (Modified GRF 1-29) has a short half-life of approximately 30 minutes.
What is the molecular weight and formula of CJC-1295 DAC?
CJC-1295 DAC has a chemical formula of C165H269N47O46 and a theoretical molecular weight of 3647.28 Da. Mass spectrometry testing verifies this mass to ensure correct sequence and linker attachment.
How should CJC-1295 DAC be reconstituted for laboratory assays?
Reconstitute lyophilized CJC-1295 DAC by adding sterile bacteriostatic water or sterile lab-grade water down the inner glass wall of the vial. Gently swirl the vial until completely dissolved. Avoid aggressive shaking to prevent peptide denaturation.
What purity levels are guaranteed for PX1 Research CJC-1295 DAC?
PX1 Research guarantees a minimum purity of 98% for all CJC-1295 DAC lots, confirmed via RP-HPLC and mass spectrometry by an independent ISO 17025 accredited laboratory.
Are endotoxin test results available for CJC-1295 DAC lots?
Yes. Every lot of CJC-1295 DAC undergoes chromogenic LAL testing to ensure endotoxin levels remain below strict limits (<0.01 EU/mg). Batch-specific COAs detailing endotoxin levels are available on request.
How should reconstituted CJC-1295 DAC solutions be stored?
Once reconstituted, liquid peptide solutions should be stored at 2°C to 8°C for short-term experimental use. For extended storage, solution aliquots should be frozen at -20°C or -80°C to prevent degradation.
What receptor targets does CJC-1295 DAC interact with in vitro?
CJC-1295 DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), stimulating intracellular cAMP production and downstream pituitary GH secretion.
Where are PX1 Research CJC-1295 DAC products manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based GMP-compliant facilities and shipped directly from distribution centers located in California and Arizona with same-day shipping on orders placed Monday through Friday.
Can institutions order CJC-1295 DAC in bulk or wholesale quantities?
Yes, PX1 Research offers institutional wholesale accounts for universities, CROs, and industrial laboratories requiring bulk quantities, custom lot reservation, and dedicated account support.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.